Developing a new treatment for Idiopathic Pulmonary Fibrosis
Official title: Translating a Novel Therapeutic Approach to the Treatment for Idiopathic Pulmonary Fibrosis
Funded at Vasarya Therapeutics, INC. · NIH-10915918 · Data updated 2026-11-12
This study is testing a new drug called VSR-H5 that aims to help people with Idiopathic Pulmonary Fibrosis (IPF) by targeting only the damaged areas of their lungs, with the hope of improving their health without causing the side effects that come with current treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vasarya Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Camden, United States) |
| Project start | September 15, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $356,250 |
| NIH project number | 1R44HL170936-01A1 |
| Project ID | NIH-10915918 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Idiopathic Pulmonary Fibrosis who are seeking alternative treatment options.
✕Less likely to help
Patients with other forms of lung disease or those who do not have a diagnosis of Idiopathic Pulmonary Fibrosis may not benefit from this research.
What this research studies
This research aims to create a novel drug candidate specifically designed to treat Idiopathic Pulmonary Fibrosis (IPF), a serious and currently incurable lung disease. The approach focuses on a compound called VSR-H5, which targets only the fibrotic areas of the lungs in patients, avoiding damage to healthy tissues. The research will involve testing this compound in laboratory settings and animal models to assess its effectiveness and safety. By selectively inhibiting the activation of harmful cells involved in fibrosis, this treatment hopes to improve patient outcomes without the severe side effects associated with existing therapies.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients suffering from Idiopathic Pulmonary Fibrosis.
How similar studies have gone: While there have been advancements in IPF treatments, this specific approach using the VSR-H5 compound is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Vasarya Therapeutics, INC.
Camden, United States Active
Researchers
- Principal investigator: Hu, Ping — Vasarya Therapeutics, INC.
- Study coordinator: Hu, Ping
Related research
Other NIH-funded projects on the same topics.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
-
Repurposing Vonoprazan as an inhaled therapy for IPF
A high-profile NIH grant is testing whether an existing drug, vonoprazan, can be inhaled to slow or reverse lung fibrosis in people with idiopathic pulmonary fibrosis (IPF).
-
Proteomic profile of IPF progression to help tailor treatments
A study will look for blood protein patterns that predict how IPF lung disease will progress in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.